<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "http://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd">
<article article-type="discussion" dtd-version="1.3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<processing-meta>
<custom-meta-group content-type="composition">
<custom-meta specific-use="newgen" xlink:href="https://www.newgen.co/">
<meta-name>Composition Vendor</meta-name>
<meta-value>Newgen KnowledgeWorks (P) Ltd.</meta-value>
</custom-meta>
</custom-meta-group>
</processing-meta>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Med</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosmed</journal-id>
<journal-title-group>
<journal-title>PLOS Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1549-1277</issn>
<issn pub-type="epub">1549-1676</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pmed.1005133</article-id>
<article-id pub-id-type="publisher-id">PMEDICINE-D-26-01637</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Perspective</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Agriculture</subject><subj-group><subject>Agronomy</subject><subj-group><subject>Plant products</subject><subj-group><subject>Tobacco</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Agriculture</subject><subj-group><subject>Crop science</subject><subj-group><subject>Plant products</subject><subj-group><subject>Tobacco</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Nicotine addiction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Social sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Nicotine addiction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Mental health and psychiatry</subject><subj-group><subject>Substance-related disorders</subject><subj-group><subject>Nicotine addiction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Substance-related disorders</subject><subj-group><subject>Nicotine addiction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Physical sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical compounds</subject><subj-group><subject>Alkaloids</subject><subj-group><subject>Nicotine</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Social sciences</subject><subj-group><subject>Law and legal sciences</subject><subj-group><subject>Regulations</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Nicotine addiction</subject><subj-group><subject>Electronic cigarettes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Social sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Addiction</subject><subj-group><subject>Nicotine addiction</subject><subj-group><subject>Electronic cigarettes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Mental health and psychiatry</subject><subj-group><subject>Substance-related disorders</subject><subj-group><subject>Nicotine addiction</subject><subj-group><subject>Electronic cigarettes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Substance-related disorders</subject><subj-group><subject>Nicotine addiction</subject><subj-group><subject>Electronic cigarettes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Behavior</subject><subj-group><subject>Habits</subject><subj-group><subject>Smoking habits</subject><subj-group><subject>Electronic cigarettes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Social sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Behavior</subject><subj-group><subject>Habits</subject><subj-group><subject>Smoking habits</subject><subj-group><subject>Electronic cigarettes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Psychological attitudes</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Social sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Psychological attitudes</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Social sciences</subject><subj-group><subject>Sociology</subject><subj-group><subject>Communications</subject><subj-group><subject>Marketing</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Tobacco control</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Availability, appeal, and addictiveness by design: Tobacco and nicotine industry deliberate targeting of youth</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Maddox</surname>
<given-names>Raglan</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2082-9612</contrib-id>
<name name-style="western">
<surname>Freeman</surname>
<given-names>Becky</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Pisinger</surname>
<given-names>Charlotta</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4617-1302</contrib-id>
<name name-style="western">
<surname>Banks</surname>
<given-names>Emily</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Tobacco Free Program, Yardhura Walani, National Centre for Aboriginal and Torres Strait Islander Wellbeing Research, National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Copenhagen, Denmark</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>We have read the journal’s policy and the authors of this manuscript have the following competing interests: BF is an expert advisor to the Cancer Council Australia tobacco issues committee, the National Health and Medical Research Council of Australia (NHMRC) e-cigarette advisory committee, and a member of the Cancer Institute vaping communications advisory panel. She has received relevant competitive grants and funding from the Australian Department of Health Disability and Ageing, NHMRC, Medical Research Future Fund, NSW Health, the Ian Potter Foundation, VicHealth, Cancer Council NSW, World Health Organization, and Healthway WA. EB is an Academic Editor for PLOS Medicine. EB AM is a member of the Cancer Institute vaping communications advisory panel and has received relevant competitive grants and funding from the Australian Department of Health, Disability and Ageing, NHMRC, Medical Research Future Fund, ASH Scotland, Government of Belgium and World Health Organization. RM has received competitive grants and funding from the Australian Department of Health, Disability and Ageing, NHMRC, Medical Research Future Fund, and Cancer Australia. CP has received competitive grants from several Danish non-profit research funds. Her professorship is paid by the non-profit Tryg Foundation, Denmark. The authors declare that they have never accepted funding or other forms of support from the tobacco or e-cigarette industries.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">raglan.maddox@anu.edu.au</email></corresp>
</author-notes>
<pub-date pub-type="epub"><day>29</day><month>5</month><year>2026</year></pub-date>
<pub-date pub-type="collection"><month>5</month><year>2026</year></pub-date>
<volume>23</volume>
<issue>5</issue>
<elocation-id>e1005133</elocation-id>
<permissions>
<copyright-year>2026</copyright-year>
<copyright-holder>Maddox et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pmed.1005133"/>
<abstract abstract-type="teaser">
<p>Contemporary tobacco and nicotine products, particularly e-cigarettes, are deliberately designed, marketed, and distributed to maximize youth appeal, uptake, dependence, and use. Youth uptake is a predictable outcome of systems designed to maximize product availability, appeal, and addictiveness.</p>
</abstract>
<abstract abstract-type="toc">
<p>In recognition of the World No Tobacco Day 2026 theme, "unmasking the appeal", this Perspective by Raglan Maddox and colleagues discusses how tobacco and nicotine products, particularly e-cigarettes, are deliberately designed and marketed to maximize youth appeal, and highlight the need for policies to ensure greater industry accountability and to tackle concerning uptake trends.</p>
</abstract>
<funding-group>
<funding-statement>EB is supported by the National Health and Medical Research Council of Australia (reference 2017742) Website: <ext-link ext-link-type="uri" xlink:href="https://www.nhmrc.gov.au/" xlink:type="simple">https://www.nhmrc.gov.au/</ext-link>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="1"/>
<table-count count="0"/>
<page-count count="5"/>
</counts>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>The 2026 World No Tobacco Day theme is “unmasking the appeal”, raising awareness of tobacco and nicotine product marketing and design, including features that increasingly appeal to adolescents. This is especially the case for e-cigarettes/vapes; vaping prevalence at ages 13–15 is on average nine times that of adults (<xref ref-type="fig" rid="pmed.1005133.g001">Fig 1</xref>), and nicotine dependence among young people is increasing [<xref ref-type="bibr" rid="pmed.1005133.ref001">1</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref002">2</xref>].</p>
<fig id="pmed.1005133.g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1005133.g001</object-id><label>Fig 1</label><caption><title>Average global prevalence of current e-cigarette use among children aged 13–15 years and adults, from countries with available data.</title><p>Data adapted from WHO global estimates [<xref ref-type="bibr" rid="pmed.1005133.ref001">1</xref>].</p></caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1005133.g001" xlink:type="simple"/></fig>
<p>Tackling appeal is therefore imperative to reversing this trend. This means appreciating that appeal goes beyond marketing, and is deliberately built into product supply and design, market environments, and regulatory conditions that serve the structural production and sustainability aims of the tobacco and nicotine industry.</p>
<p>Tobacco and nicotine products intentionally attract attention, reduce aversion, and sustain use, particularly among young people who represent the next generation of consumers as smoking rates decline [<xref ref-type="bibr" rid="pmed.1005133.ref003">3</xref>]. The commercial tobacco and nicotine industry generates profit through the creation and maintenance of addiction, and lifetime nicotine addiction largely occurs when use starts while the brain is developing, in childhood and adolescence. Youth uptake must therefore be understood not as an unintended outcome, but as a fundamental industry aim, necessary for industry profits and survival, and a predictable outcome of systems that maximize availability, appeal, and addictiveness.</p>
<p>Understanding these key drivers is essential for effective regulations, policies, and programs to reduce tobacco use and nicotine addiction and protect the health of young people. This is especially important given the growing evidence regarding the adverse health impacts of e-cigarettes, particularly for youth, including addiction, toxicity through inhalation, poisoning, burns and injuries, lung injury, increased smoking uptake, and concerning findings relating to cardiovascular, respiratory, and carcinogenic effects [<xref ref-type="bibr" rid="pmed.1005133.ref002">2</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref004">4</xref>]. Furthermore, the long-term impacts of e-cigarettes on many important clinical conditions remain uncertain [<xref ref-type="bibr" rid="pmed.1005133.ref002">2</xref>].</p>
</sec>
<sec id="sec002">
<title>The evolution of the industry narrative</title>
<p>Industry messaging about the purported benefits of vaping and other nicotine products has shifted from individual smoking cessation-oriented claims toward broader and often unsubstantiated narratives of population benefit that position youth uptake as incidental, unavoidable, or even protective against future smoking [<xref ref-type="bibr" rid="pmed.1005133.ref005">5</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref006">6</xref>]. This framing relocates responsibility from industry practices onto individual behavior while preserving market legitimacy and obscuring the structural and commercial drivers of nicotine dependence [<xref ref-type="bibr" rid="pmed.1005133.ref005">5</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref006">6</xref>].</p>
<p>Consistent with longstanding industry strategies to manufacture doubt and delay regulation, contemporary “harm reduction” narratives emphasize uncertainty, personal choice, and the inevitability of nicotine use, while minimizing the role of product design, marketing, and commercial systems in producing addiction [<xref ref-type="bibr" rid="pmed.1005133.ref005">5</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref006">6</xref>]. Importantly, this framing also reproduces colonial patterns of reasoning, recasting structurally produced harms as matters of individual responsibility, which legitimizes continued expansion into younger populations [<xref ref-type="bibr" rid="pmed.1005133.ref005">5</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref006">6</xref>]. Industry and investor communications continue to frame younger generations as critical to the long-term sustainability of nicotine markets, reinforcing the commercial importance of ongoing youth uptake and dependence.</p>
</sec>
<sec id="sec003">
<title>Why youth uptake is predictable</title>
<p>E-cigarette appeal arises from interacting features across product design, market environments, and regulatory conditions. These features operate synergistically, creating conditions in which initiation, dependence, and sustained use are likely [<xref ref-type="bibr" rid="pmed.1005133.ref006">6</xref>].</p>
<p>At the product level, flavors [<xref ref-type="bibr" rid="pmed.1005133.ref007">7</xref>], sensory appeal [<xref ref-type="bibr" rid="pmed.1005133.ref008">8</xref>], device aesthetics, nicotine salts, digital integration, and misleading labeling all increase product palatability and attractiveness among young people. For example, nicotine salts allow smoother inhalation and higher nicotine delivery, accelerating dependence, particularly among people who have not previously used nicotine [<xref ref-type="bibr" rid="pmed.1005133.ref008">8</xref>]. Devices increasingly incorporate social and digital features, embedding nicotine use within everyday routines and online environments. These features also increase visibility, peer diffusion, and social normalization among young people.</p>
<p>Higher nicotine concentration product use has increased substantially over time: from 2017 to 2022, the share of products containing ≥5% nicotine strength increased by 1,486% [<xref ref-type="bibr" rid="pmed.1005133.ref009">9</xref>]. Products are marketed as long-lasting and continuously available for use, and use patterns often include ubiquitous “grazing”: repeatedly inhaling small series of puffs throughout the day. Rapid product innovation and designs intended to facilitate frequent and sustained nicotine exposure reinforce these patterns [<xref ref-type="bibr" rid="pmed.1005133.ref008">8</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref009">9</xref>]. Products are also designed to be easy to use and integrated throughout normal daily routines and activities [<xref ref-type="bibr" rid="pmed.1005133.ref008">8</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref009">9</xref>]. Product designs, affordability, widespread availability, and equivalence framings (e.g., puff-to-cigarette comparisons) normalize experimentation, uptake, consumption, and sustained nicotine use among young people. This pattern of continuous product change reflects a deliberate strategy to sustain use and dependence [<xref ref-type="bibr" rid="pmed.1005133.ref006">6</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref009">9</xref>]. Misleading descriptors such as “tobacco-free” further obscure risk.</p>
<p>Promotion occurs within highly permissive digital and retail environments. Social media marketing, influencer partnerships, and youth-oriented branding increase exposure and normalize use at scale [<xref ref-type="bibr" rid="pmed.1005133.ref010">10</xref>], often beyond the reach of existing regulation. These dynamics are enabled by regulatory gaps. Products frequently enter markets without robust pre-market evidence, standards remain inconsistent, and enforcement is often weak. These conditions also contribute to unregulated and illicit markets, which are a predictable consequence of oversupply, weak regulation, and profit-driven distribution [<xref ref-type="bibr" rid="pmed.1005133.ref011">11</xref>].</p>
<p>Taken together, these conditions make youth uptake of products an entirely foreseeable and system-driven outcome. Importantly, exposure to appealing product environments is not evenly distributed. Youth and communities experiencing structural disadvantage are more heavily targeted and less protected by regulation. This includes Indigenous peoples, racialized populations, LGBTQA+ communities, and those facing socioeconomic disadvantage, reflecting patterns shaped by colonization, racism, and commercial targeting [<xref ref-type="bibr" rid="pmed.1005133.ref012">12</xref>]. Describing these groups as “vulnerable” risks obscuring the structural drivers of harm [<xref ref-type="bibr" rid="pmed.1005133.ref013">13</xref>]. The issue is not inherent susceptibility, but a failure of systems to provide adequate protection, allowing predatory industries to exploit these gaps [<xref ref-type="bibr" rid="pmed.1005133.ref012">12</xref>].</p>
</sec>
<sec id="sec004">
<title>Policy implications: Regulating design and supply, not just marketing</title>
<p>Product design and other factors contributing to appeal should be recognized as key determinants of health, not as neutral features. If appeal is engineered, policy must address the systems that produce and sustain it. This requires adopting comprehensive tobacco advertising, promotion, and sponsorship bans, as well as regulating product design, supply, and the broader commercial environment [<xref ref-type="bibr" rid="pmed.1005133.ref012">12</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref014">14</xref>].</p>
<p>Priorities include: pre-market product standards, where the tobacco industry is legally required to prove product safety, as in Norway; restrictions on flavors and design features (including bans); stronger control of retail and digital environments (e.g., strict tobacco retailer licensing systems, limiting retailer density, strong enforcement, and substantial penalties for violations); and full implementation of WHO Framework Convention on Tobacco Control, including high tobacco taxes, comprehensive advertising and sponsorship bans, 100% smoke-free public spaces, large graphic health warnings, restrictions on youth access, and measures to combat illicit trade [<xref ref-type="bibr" rid="pmed.1005133.ref014">14</xref>]. This also includes Article 5.3 protections against industry interference, which recognize the fundamental conflict between public health and tobacco industry interests and require governments to protect health policy from the commercial and other vested interests of the tobacco industry through transparency, limiting interactions to those strictly necessary for regulation, and rejecting partnerships or voluntary agreements with tobacco and nicotine companies [<xref ref-type="bibr" rid="pmed.1005133.ref014">14</xref>]. A precautionary approach is needed, placing the burden of proof of product safety on industry rather than on populations exposed to harms.</p>
</sec>
<sec id="sec005" sec-type="conclusions">
<title>Conclusions</title>
<p>Unmasking appeal requires recognizing that attractiveness is not incidental but a deliberate strategy within commercial and regulatory systems that enable this harm. Youth uptake is not a failure of individual choice or a lack of awareness of harms, but a predictable outcome of an industry structured and incentivised to generate and sustain addiction. Effective protection depends on governing commercial practices, and more fundamentally, on addressing the systems that allow harmful products to be created, promoted, and made widely available [<xref ref-type="bibr" rid="pmed.1005133.ref006">6</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref011">11</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref012">12</xref>,<xref ref-type="bibr" rid="pmed.1005133.ref014">14</xref>]. This shifts policy from managing risk to addressing its source: the commercial tobacco and nicotine industries.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pmed.1005133.ref001"><label>1</label><mixed-citation publication-type="book" xlink:type="simple"><collab>World Health Organization</collab>. <source>WHO global report on trends in prevalence of tobacco use 2000-2024 and projections 2025-2030</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2025</year>.</mixed-citation></ref>
<ref id="pmed.1005133.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Banks</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Yazidjoglou</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Brown</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nguyen</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Martin</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Beckwith</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Electronic cigarettes and health outcomes: umbrella and systematic review of the global evidence</article-title>. <source>Med J Aust</source>. <year>2023</year>;<volume>218</volume>(<issue>6</issue>):<fpage>267</fpage>–<lpage>75</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5694/mja2.51890" xlink:type="simple">10.5694/mja2.51890</ext-link></comment> <object-id pub-id-type="pmid">36939271</object-id></mixed-citation></ref>
<ref id="pmed.1005133.ref003"><label>3</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Johnston</surname> <given-names>M</given-names></name>. <source>Young smokers – prevalence, trends, implications and related demographic trends – memorandum to Dr. Robert B. Seligman</source>. <publisher-loc>San Francisco, CA</publisher-loc>: <publisher-name>UCSF Industry Documents Library</publisher-name>; <year>1985</year>.</mixed-citation></ref>
<ref id="pmed.1005133.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Golder</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Hartwell</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Barnett</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Nash</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Petticrew</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Glover</surname> <given-names>RE</given-names></name>. <article-title>Vaping and harm in young people: umbrella review</article-title>. <source>Tob Control</source>. <year>2025</year>;:tc-2024-059219. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/tc-2024-059219" xlink:type="simple">10.1136/tc-2024-059219</ext-link></comment> <object-id pub-id-type="pmid">40829950</object-id></mixed-citation></ref>
<ref id="pmed.1005133.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maddox</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Diaz</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Waa</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Teddy</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Telford</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Pope</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Resisting industry narratives: guidance to avoid tobacco and nicotine industry framing</article-title>. <source>Health Promot Int</source>. <year>2024</year>;<volume>39</volume>(<issue>6</issue>):daae143. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/heapro/daae143" xlink:type="simple">10.1093/heapro/daae143</ext-link></comment> <object-id pub-id-type="pmid">39569484</object-id></mixed-citation></ref>
<ref id="pmed.1005133.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maddox</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Heris</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Waa</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Teddy</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Upton</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Henderson</surname> <given-names>PN</given-names></name>, <etal>et al</etal>. <article-title>Colonial harm in new packaging: indigenous critiques of the tobacco industry’s “harm reduction” rhetoric</article-title>. <source>Health Promot Int</source>. <year>2025</year>;<volume>40</volume>(<issue>4</issue>):daaf111. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/heapro/daaf111" xlink:type="simple">10.1093/heapro/daaf111</ext-link></comment> <object-id pub-id-type="pmid">40728114</object-id></mixed-citation></ref>
<ref id="pmed.1005133.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Meernik</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Baker</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Kowitt</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>Ranney</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Goldstein</surname> <given-names>AO</given-names></name>. <article-title>Impact of non-menthol flavours in e-cigarettes on perceptions and use: an updated systematic review</article-title>. <source>BMJ Open</source>. <year>2019</year>;<volume>9</volume>(<issue>10</issue>):e031598. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmjopen-2019-031598" xlink:type="simple">10.1136/bmjopen-2019-031598</ext-link></comment> <object-id pub-id-type="pmid">31619431</object-id></mixed-citation></ref>
<ref id="pmed.1005133.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leventhal</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Madden</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Peraza</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Schiff</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Lebovitz</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Whitted</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Effect of exposure to e-cigarettes with salt vs free-base nicotine on the appeal and sensory experience of vaping: a randomized clinical trial</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>1</issue>):e2032757. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamanetworkopen.2020.32757" xlink:type="simple">10.1001/jamanetworkopen.2020.32757</ext-link></comment> <object-id pub-id-type="pmid">33433597</object-id></mixed-citation></ref>
<ref id="pmed.1005133.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ali</surname> <given-names>FRM</given-names></name>, <name name-style="western"><surname>Seaman</surname> <given-names>EL</given-names></name>, <name name-style="western"><surname>Crane</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Schillo</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>King</surname> <given-names>BA</given-names></name>. <article-title>Trends in US e-cigarette sales and prices by nicotine strength, overall and by product and flavor type, 2017–2022</article-title>. <source>Nicotine Tobacco Res</source>. <year>2023</year>;<volume>25</volume>(<issue>5</issue>):<fpage>1052</fpage>–<lpage>6</lpage>.</mixed-citation></ref>
<ref id="pmed.1005133.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Suttiratana</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Sen</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Kong</surname> <given-names>G</given-names></name>. <article-title>E-cigarette marketing on social media: a scoping review</article-title>. <source>Curr Addict Rep</source>. <year>2023</year>;<volume>10</volume>(<issue>1</issue>):<fpage>29</fpage>–<lpage>37</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40429-022-00463-2" xlink:type="simple">10.1007/s40429-022-00463-2</ext-link></comment> <object-id pub-id-type="pmid">41001189</object-id></mixed-citation></ref>
<ref id="pmed.1005133.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dessaix</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Maddox</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Stone</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Freeman</surname> <given-names>B</given-names></name>. <article-title>Policy incoherence: Leadership needed to combat illicit tobacco and end tobacco oversupply</article-title>. <source>Aust N Z J Public Health</source>. <year>2025</year>;<volume>49</volume>(<issue>5</issue>):<fpage>100278</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.anzjph.2025.100278" xlink:type="simple">10.1016/j.anzjph.2025.100278</ext-link></comment> <object-id pub-id-type="pmid">41033930</object-id></mixed-citation></ref>
<ref id="pmed.1005133.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maddox</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Bradbrook</surname> <given-names>SK</given-names></name>. <article-title>Building love and justice, ending harms: a framework for abolishing the tobacco and nicotine industry</article-title>. <source>Health Promot Int</source>. <year>2025</year>;<volume>40</volume>(<issue>4</issue>):daaf103. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/heapro/daaf103" xlink:type="simple">10.1093/heapro/daaf103</ext-link></comment> <object-id pub-id-type="pmid">40709579</object-id></mixed-citation></ref>
<ref id="pmed.1005133.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Katz</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Hardy</surname> <given-names>B-J</given-names></name>, <name name-style="western"><surname>Firestone</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lofters</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Morton-Ninomiya</surname> <given-names>ME</given-names></name>. <article-title>Vagueness, power and public health: use of ‘vulnerable’ in public health literature</article-title>. <source>Critical Public Health</source>. <year>2019</year>;<volume>30</volume>(<issue>5</issue>):<fpage>601</fpage>–<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/09581596.2019.1656800" xlink:type="simple">10.1080/09581596.2019.1656800</ext-link></comment></mixed-citation></ref>
<ref id="pmed.1005133.ref014"><label>14</label><mixed-citation publication-type="book" xlink:type="simple"><collab>World Health Organization</collab>. <source>World Health Organization framework convention on tobacco control</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2003</year>.</mixed-citation></ref>
</ref-list>
</back>
</article>